Skip to main content

Oncology

Oncology

Oncology

Safe and convenient packaging for the parenteral delivery of oncology therapies

The development of new therapies for the treatment of cancer is a major focus for pharmaceutical companies as the global prevalence of the disease continues to rise. In 2018 targeted small molecule and biologic treatments made up around 91% of the late-stage oncology drug development pipeline, with alternative non-specific therapies such as cytotoxic agents, radiotherapies and hormones accounting for the remainder. Next Generation Biotherapeutics - cell, gene and nucleotide therapies – are particularly promising for oncology.

Over 50% (by volume) of cancer drugs are delivered parenterally, via injection or infusion. The vast majority of these drugs are classified as antineoplastics, drugs that work by preventing, inhibiting or halting the development of a neoplasm or tumor. Examples include: antimetabolites, plant base products, platinum therapies, monoclonal antibodies (mAbs), antibiotics derived from microorganisms, and alkylating agents. Most of these are small molecule drugs, mAbs being the important exception.

Glass vials or bottles and ampoules are used widely for oncology drug delivery. The majority of these drugs are supplied in liquid form, though lyophilization and reconstitution at the point of use is also routine. Drug stability and sterility throughout the supply chain are critical for patient safety, with particulates a notable concern, due to their ability to trigger immunogenicity and impact patient health*.

The wide variety of glass packaging available, along with the maturity of filling, sealing and labelling technology are important benefits and support the development of an optimised solution for every drug. Beyond these practicalities glass is prized for:

  • Chemical stability, for a wide range of formulations
  • Impermeability to gases such as O², which may compromise drug stability
  • Heat resistance, suitability for hot filling and resorting
  • Clarity, ease of inspection
  • Mechanical resistance (notably molded glass) which is particularly important for the manufacture of cytotoxic drugs.

SGD Pharma offers a wide range of Type I & Type II parenteral products to meet the oncology market’s need for the most inert packaging and that answer directly to the demanding requirements of high value oncology products and novel cancel therapies. This range includes effective solutions for sensitive drugs, for high viscosity formulations and for those with high pH. The quality of SGD Pharma glass is extremely high and the company continues to innovate to meet evolving requirements. For example, the Sterinity platform has recently been introduced for the Ready-To-Use market.

* https://www.degruyter.com/view/...

Life Science

Life Science

Life Science

An extensive portfolio of glass containers for the testing, analysis and diagnostics that drive the life science industries.

The lifesciences industry is driven by data, from rapid, point of care diagnostic testing for healthcare to increasingly sophisticated analyses that generate the information needed to develop new drugs. In vitro testing - literal translation ‘in glass’ – is routine, convenient, and cost-efficient relative to in vivo methods such as the clinical trials associated with pharmaceutical development. However, more generally glass containers of all types are a vital consumable across the life sciences for activities such as:

  • sampling and sample storage
  • cell culturing
  • liquid handling and dispensing
  • reagent, media and standards preparation and storage
  • stability assessment.

Glass containers are chosen for these applications because they are:

  • chemically inert and impermeable to gases
  • easy to clean and sterilize, allowing re-use for many applications
  • commercially available in a wide range of sizes and designs
  • heat resistant

SGD Pharma’s broad portfolio of glass containers extends to molded products in Type I, Type II and Type III glass, in both clear and amber glass. A choice of neck finishes, for many products, makes it straightforward to match containers to specific applications; customized and plasticized products are readily available.

SGD Pharma is officially on WeChat

We are thrilled to announce the launch of our official WeChat public account, dedicated for China market.

By following us on Wechat, you can easily access our company information, product applications and innovations.

You can also leave us an instant message to exchange ideas with us on this new platform.

Simply scan the QR code or search “SGD Pharma” on WeChat to follow us now.

CPhI Festival of Pharma - Free Invitation

CPhI Festival of Pharma - Free Invitation

Stand No. :

Visiter le site web

Save the date!

CPhI organizes the first 100% digital experience that will connect various players in the pharmaceutical sector.

This event will take place from October 5 to 16, 2020. 

Join SGD Pharma and discover our latest hot news during this Festival of Pharma. 

Register and get your free invitation

SGD Pharma will do everything to avoid vial shortages

Drugmakers are warning of a potential shortage of vials to bottle future COVID-19 vaccines, but their rush to secure supplies risks making matters worse, some major medical equipment manufacturers warn.

Source : www.reuters.com - Matthias Blamont, Ludwig Burger - Reuters 

 

How is SGD Pharma Innovating through the Pandemic and Beyond to Define the Future of Healthcare?

Pharma glass specialist’s positive response to Covid-19 crisis

As a key supplier to the global pharmaceutical industry, SGD Pharma is well versed in the process of contingency planning. This experience has greatly assisted the specialist glass packaging manufacturer in implementing its response to the Covid-19 pandemic, with melting at all five production sites continuing to run at full capacity throughout the crisis.

Pharmapack

Covid-19: Donation of protective materials to hospitals in Créteil

Charity operation with the nursing staff!

How is SGD Pharma preparing the Future of Healthcare?

SGD Pharma to participate to the Road to CPHI Milano.

The Road To CPHI Milano is a new adventure – taking place in the run-up to CPhI Worldwide 2020 in Milan. From September 14 to October 9, Pharma’s Almanac will be discovering the future of healthcare on a 7,000+ mile journey around 25 countries – and companies - in Europe.

Subscribe to